Evidence map›Paper›PMID 39060911›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2024

In silico designing of multi-epitope vaccine against canine parvovirus using reverse vaccinology.

Tamiris Silva Lopes, Brenda Picoli Gheno, Luiza Dos Santos Miranda, Joana Detofano, Md Anik Ashfaq Khan, André Felipe Streck

Abstract read
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tamiris Silva LopesUniversidade de Caxias do Sul, Caxias do Sul, RS, Brazil.
Brenda Picoli GhenoUniversidade de Caxias do Sul, Caxias do Sul, RS, Brazil.
Luiza Dos Santos MirandaUniversidade de Caxias do Sul, Caxias do Sul, RS, Brazil.
Joana DetofanoUniversidade de Caxias do Sul, Caxias do Sul, RS, Brazil.
Md Anik Ashfaq KhanUniversity of Leipzig, Leipzig, Germany.
André Felipe StreckUniversidade de Caxias do Sul, Caxias do Sul, RS, Brazil. afstreck@ucs.br.ORCID http://orcid.org/0000-0002-4798-0777

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico Conselho Nacional de Desenvolvimento Científico e TecnológicoCoordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul
6 · The paper itself

Abstract

Canine parvovirus (CPV-2) is a highly contagious virus affecting dogs worldwide, posing a significant threat. The VP2 protein stands out as the predominant and highly immunogenic structural component of CPV-2. Soon after its emergence, CPV-2 was replaced by variants known as CPV-2a, 2b and 2c, marked by changes in amino acid residue 426 of VP2. Additional amino acid alterations have been identified within VP2, with certain modifications serving as signatures of emerging variants. In Brazil, CPV-2 outbreaks persist with diverse VP2 profiles. Vaccination is the main preventive measure against the virus. However, the emergence of substitutions presents challenges to conventional vaccine methods. Commercial vaccines are formulated with strains that usually do not match those currently circulating in the field. To address this, the study aimed to investigate CPV-2 variants in Brazil, predict epitopes, and design an in silico vaccine tailored to local variants employing reverse vaccinology. The methodology involved data collection, genetic sequence analysis, and amino acid comparison between field strains and vaccines, followed by the prediction of B and T cell epitope regions. The predicted epitopes were evaluated for antigenicity, allergenicity and toxicity. The final vaccine construct consisted of selected epitopes linked to an adjuvant and optimized for expression in Escherichia coli. Structural predictions confirmed the stability and antigenicity of the vaccine, while molecular docking demonstrated interaction with the canine toll-like receptor 4. Molecular dynamics simulations indicated a stable complex formation. In silico immune simulations demonstrated a progressive immune response post-vaccination, including increased antibody production and T-helper cell activity. The multi-epitope vaccine design targeted prevalent CPV-2 variants in Brazil and potentially other regions globally. However, experimental validation is essential to confirm our in silico findings.

Indexed as

Computer SimulationDog DiseasesParvoviridae InfectionsParvovirus, CanineViral VaccinesAnimalsBrazilCapsid ProteinsDogsEpitopesEpitopes, B-LymphocyteEpitopes, T-LymphocyteVaccinologyCapsid ProteinsEpitopesEpitopes, B-LymphocyteEpitopes, T-LymphocyteViral VaccinesBrazilCanine parvovirusEpitopeImmunoinformaticsVaccine

Identifiers

PMID39060911
PMCPMC11405728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.